Fig. 5

Kinetics of RB-312 cellular function in combination with anti-PD-L1. NT, convCAR, cRB-312 and RB‐312 were stimulated with either FaDu cells overexpressing PDL1 (PDL1 OE) or FaDu engineered with PDL1 knockout (PDL1 KO; A–E), or stimulated with FaDu cells with and without addition of atezolizumab (10 ug/ml, F–J) at 3:1 E:T ratio for 6 days. Representative kinetics of CAR-T proliferation, IFN‐γ, IL-2, TNF‐α secretion and PD1 expression were obtained at day 2, 3 and 6 as indicated